It seems so simple. We should be able to use proteomics to better pick winners when it comes to b/tsDMARDs in RA. Why is it hard? I guess: - theory ≠ practice - too many other factors - it's too easy not to Yet I hope/believe, one day we'll do better. #ACR23 ABST0427 @RheumNow https://t.co/5VBVp3KOJN

If you're >65 years old & have new RA, you start a DMARD, right? At worst, sometime in the first year? US Medicare data 2008-17 n=33,373 only 30% have a DMARD on file (of which bDMARD <10%) >5% on PNL alone Do we hate old people with RA?😔 @JihaRheum #ACR23 ABST0433 @RheumNow https://t.co/1CUXAh3fi0

I underestimated how much joy not-bankrupting our healthcare system would bring me ADA & RTX biosimilars have been wonderful; excited for IL6's to join the party @RheumNow #ACR23 Abstr0445 https://t.co/HGwi37rZpd

Year in Review by Dr. P Seo NORD-STAR trial: ⭐️Abatacept or Certolizumab >> Tociluzumab > triple therapy in tx of 812 early RA patients based on clinical & radiographic results ➡️tx-naive, all got MTX ➡️mod-sev dz activity ➡️randomized to 48 wks therapy #ACR23 @RheumNow https://t.co/vy2uYuyOse

Interesting question... but feels like some time related bias or perhaps confounding? Seems implausible that MTX & biologic would be protective for PsO & harmful for PsA @RheumNow #ACR23 Abstr 0498 https://t.co/pSRoLHRTAm

C-VIEW study on certolizumab use in preventing anterior uveitis in high risk pts with axSpA. All pts were B27+ w/ at least one episode of anterior uveitis Uveitis flares lower in certolizumab group compared to non-bDMARD use @RheumNow #ACR23 Abs#0524 https://t.co/CfnhzStBMv

You should not tire of hearing this! Phase2 RCT of #dazodalibep -CD40L antagonist for #extra glandular & could also have #glandular problems in #Sjogrens was + improving Facit #fatigue & ESSPRI, etc. #GameChanger #ACR23 #ACRbest ⁦@ACRheum⁩ ⁦@RheumNow⁩ Pos#L10 https://t.co/DfChrAyslL